US speciality biz, India rebound help Sun Pharma shine in Q2
The management intends to ramp up the speciality business to a reasonable scale before allocating investments in new areas. Synopsis India business, contributing a third of the company’s consolidated revenues, grew on the back of a recovery in non-Covid drug therapies leading to gains for the industry leader. The market is gradually moving back to … Read more
